Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therapeutic option for cancer treatment. However, modulat...

Full description

Bibliographic Details
Main Authors:	Juwon Lee, Youngjin Han, Wenyu Wang, HyunA Jo, Heeyeon Kim, Soochi Kim, Kyung-Min Yang, Seong-Jin Kim, Danny N. Dhanasekaran, Yong Sang Song
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Biomolecules
Subjects:	phytochemical immune checkpoint PD-1 PD-L1 cancer immunotherapy
Online Access:	https://www.mdpi.com/2218-273X/11/8/1107

Similar Items

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
by: Deniz Can Guven, et al.
Published: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
by: Vickram A S, et al.
Published: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)

Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
by: Ahmed M. Basudan
Published: (2022-12-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)

Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors
by: Lucy Guan, et al.
Published: (2023-03-01)

Immune checkpoint inhibitors and prostate cancer: a new frontier?
by: Alessandra Modena, et al.
Published: (2016-04-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
by: Julie M. Collins, et al.
Published: (2018-08-01)

Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors
by: Qi Zhang, et al.
Published: (2024-12-01)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
by: Connor Frey, et al.
Published: (2024-07-01)

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer
by: Da Hyun Kang, et al.
Published: (2022-08-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
by: Lijun Peng, et al.
Published: (2022-09-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
by: Alberto Bongiovanni, et al.
Published: (2021-05-01)

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma
by: Zeping Wang, et al.
Published: (2024-10-01)

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
by: Dandan Song, et al.
Published: (2024-11-01)

Efficacy and safety of immune checkpoint blockade for brain metastases
by: Maya Harary, et al.
Published: (2019-06-01)

Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
by: Giulio Metro, et al.
Published: (2021-09-01)

First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population
by: Feiyang Zhang, et al.
Published: (2024-07-01)

Comprehensive overview of biomarkers to predict response to immune checkpoint therapy in lung cancer
by: Kriti Jain, et al.
Published: (2023-01-01)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
by: Emily Allen, et al.
Published: (2023-10-01)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
by: Rita Balsano, et al.
Published: (2023-03-01)

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
by: Soumaya Karaki, et al.
Published: (2016-11-01)

An overview of immune checkpoint inhibitor toxicities in bladder cancer
by: Avenie Mavadia, et al.
Published: (2024-12-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
by: Jacek Mackiewicz, et al.
Published: (2017-03-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
by: Arefeh Zabeti Touchaei, et al.
Published: (2024-03-01)

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura
by: James T. Boothe, et al.
Published: (2017-11-01)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
by: Yunkai Xie, et al.
Published: (2022-10-01)

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
by: Randolph J. Noelle, et al.
Published: (2023-09-01)